These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 25160011)

  • 1. Older age at rheumatoid arthritis onset and comorbidities correlate with less Health Assessment Questionnaire-Disability Index and Clinical Disease Activity Index response to etanercept in the RADIUS 2 registry.
    Martin WJ; Shim M; Paulus HE; Chaudhari S; Feng J; Elashoff D; Hahn TJ; Ranganath VK;
    J Clin Rheumatol; 2014 Sep; 20(6):301-5. PubMed ID: 25160011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies.
    Schiff MH; Yu EB; Weinblatt ME; Moreland LW; Genovese MC; White B; Singh A; Chon Y; Woolley JM
    Drugs Aging; 2006; 23(2):167-78. PubMed ID: 16536638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept.
    Tanaka Y; Yamanaka H; Saito K; Iwata S; Miyagawa I; Seto Y; Momohara S; Nagasawa H; Kameda H; Kaneko Y; Izumi K; Amano K; Takeuchi T
    Mod Rheumatol; 2012 Apr; 22(2):186-94. PubMed ID: 21901357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of functional improvement and pain reduction in rheumatoid arthritis patients who achieved low disease activity with disease-modifying antirheumatic drugs: a retrospective study of the FIRST Registry.
    Ochi S; Sonomoto K; Nakayamada S; Tanaka Y
    Arthritis Res Ther; 2024 Jul; 26(1):140. PubMed ID: 39061106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remission in rheumatoid arthritis patients treated with etanercept monotherapy: clinical practice and clinical trial experience.
    Cannon GW; Wang BC; Park GS; Koenig A; Collier DH; Keystone EC
    Clin Exp Rheumatol; 2013; 31(6):919-25. PubMed ID: 24237999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation of disease-modifying anti-rheumatic drugs and clinical outcomes in the Rheumatoid Arthritis DMARD Intervention and Utilisation Study 2 (RADIUS 2).
    Gibofsky A; Cannon GW; Harrison DJ; Joseph GJ; Bitman B; Chaudhari S; Collier DH
    Clin Exp Rheumatol; 2015; 33(3):297-301. PubMed ID: 25738333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis.
    Ranganath VK; Maranian P; Elashoff DA; Woodworth T; Khanna D; Hahn T; Sarkisian C; Kremer JM; Furst DE; Paulus HE
    Rheumatology (Oxford); 2013 Oct; 52(10):1809-17. PubMed ID: 23813577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability.
    Baumgartner SW; Fleischmann RM; Moreland LW; Schiff MH; Markenson J; Whitmore JB
    J Rheumatol; 2004 Aug; 31(8):1532-7. PubMed ID: 15290731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life and disability in patients with rheumatoid, early rheumatoid and early psoriatic arthritis treated with etanercept.
    Picchianti-Diamanti A; Germano V; Ferlito C; Migliore A; D'Amelio R; Laganà B
    Qual Life Res; 2010 Aug; 19(6):821-6. PubMed ID: 20373036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of age at disease onset on disease activity and disability: results from the Ontario Best Practices Research Initiative.
    Ruban TN; Jacob B; Pope JE; Keystone EC; Bombardier C; Kuriya B
    Clin Rheumatol; 2016 Mar; 35(3):759-63. PubMed ID: 26245721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis.
    Bae SC; Gun SC; Mok CC; Khandker R; Nab HW; Koenig AS; Vlahos B; Pedersen R; Singh A
    BMC Musculoskelet Disord; 2013 Jan; 14():13. PubMed ID: 23294908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug.
    Hyrich KL; Lunt M; Dixon WG; Watson KD; Symmons DP;
    Rheumatology (Oxford); 2008 Jul; 47(7):1000-5. PubMed ID: 18420660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Disease Activity Score in 28 joints with ESR (DAS28), Clinical Disease Activity Index (CDAI), Health Assessment Questionnaire Disability Index (HAQ-DI) & Routine Assessment of Patient Index Data with 3 measures (RAPID3) for assessing disease activity in patients with rheumatoid arthritis at initial presentation.
    Kumar BS; Suneetha P; Mohan A; Kumar DP; Sarma KVS
    Indian J Med Res; 2017 Nov; 146(Supplement):S57-S62. PubMed ID: 29578196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing clusters of comorbidities in rheumatoid arthritis: a machine learning approach.
    Solomon DH; Guan H; Johansson FD; Santacroce L; Malley W; Guo L; Litman H
    Arthritis Res Ther; 2023 Nov; 25(1):224. PubMed ID: 37993918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Niclosamide as an adjuvant to etanercept in treatment patients with active rheumatoid arthritis: an 8-week randomized controlled pilot study.
    Al-Gareeb AIA; Gorial FI; Mahmood AS
    Clin Rheumatol; 2018 Oct; 37(10):2633-2641. PubMed ID: 29882203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Onset of action of etanercept in rheumatoid arthritis based on patient-reported outcomes.
    Dougados M; Ripert M; Hilliquin P; Brocq O; Brault Y; Logeart I
    Clin Exp Rheumatol; 2012; 30(2):266-8. PubMed ID: 22325048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register.
    Iannone F; Gremese E; Gallo G; Sarzi-Puttini P; Botsios C; Trotta F; Gasperini S; Galeazzi M; Adami S; Cantini F; Sebastiani M; Gorla R; Marchesoni A; Giardina A; Foti R; Mele A; Bruschi E; Bagnato G; Erre GL; Lapadula G;
    Clin Rheumatol; 2014 Jan; 33(1):31-7. PubMed ID: 23954923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis.
    Koike T; Harigai M; Inokuma S; Ishiguro N; Ryu J; Takeuchi T; Tanaka Y; Yamanaka H; Fujii K; Yoshinaga T; Freundlich B; Suzukawa M
    Rheumatol Int; 2012 Jun; 32(6):1511-9. PubMed ID: 21327436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
    Smolen JS; Szumski A; Koenig AS; Jones TV; Marshall L
    Arthritis Res Ther; 2018 Jan; 20(1):8. PubMed ID: 29338762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study.
    Schabert VF; Bruce B; Ferrufino CF; Globe DR; Harrison DJ; Lingala B; Fries JF
    Curr Med Res Opin; 2012 Apr; 28(4):569-80. PubMed ID: 22236091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.